Sangon Biotech
Pioneering DNA synthesis and advanced biotechnologies since 2003
Pioneering DNA synthesis and advanced biotechnologies since 2003
Sangon Biotech is a leading biotechnology company, specializing in DNA synthesis and advanced biotechnologies. Founded in 2003 as a Sino-foreign joint venture, the company has gained global recognition for its expertise in DNA synthesis. In 2006, an investment of 50 million facilitated the establishment of a manufacturing and industrial base at Songjiang Industrial Park, which is now fully operational.
With a diverse product range including DNA synthesis, DNA sequencing, gene synthesis, peptide synthesis, and more, Sangon Biotech has positioned itself as a key player in the biotechnology industry. The latest venture round investment on 19 April 2023 amounted to CNY2.00B and involved notable investors such as Novo Holdings, Citic PE, GL Capital, Huagai Capital, Greenwoods Investment, Shanghai Jinglin Asset Management, Defu Capital, and CDB Science and Technology Innovation.
Sangon Biotech's commitment to pioneering DNA synthesis and advanced biotechnologies since 2003 underscores its potential for growth and innovation in the biotechnology sector, making it an attractive prospect for venture capital investment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | CNY2.00B | 8 |
|
19 Apr 2023 |
| Series A | $6.20M | 1 |
|
01 Jul 2010 |
No recent news or press coverage available for Sangon Biotech.
We care about your data, and we'd love to use cookies make your experience better.
